The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments

Expert Opinion on Drug Metabolism and Toxicology

Volumn 14, Issue 12, 2018, Pages 1287-1302

  Garcia Ropero, Alvaro ^a   Badimon, Juan J ^a   Santos Gallego, Carlos G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Canagliflozin; dapagliflozin; empagliflozin; heart failure; pharmacodynamics; pharmacokinetics; SGLT2 inhibitors; type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLP 1 RECEPTOR ANTAGONIST; INSULIN; MEGLITINIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM PROTON EXCHANGE PROTEIN; SOTAGLIFLOZIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

CARDIOLOGY; CARDIOVASCULAR FUNCTION; DIABETIC PATIENT; DIARRHEA; DIURESIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; FEMALE GENITAL TRACT INFECTION; FUNGAL GENITAL INFECTION; HEADACHE; HEART FAILURE; HEART MUSCLE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; ANIMAL; CARDIOVASCULAR DISEASE; COMPLICATION; DRUG EFFECT; HOSPITALIZATION; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; PHARMACOLOGY; STATISTICS AND NUMERICAL DATA;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85058218252     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2018.1551877     Document Type: Review

References (115)

1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: A report from the American Heart Association [Internet]. Circulation. 2018. Available from: http://circ.ahajournals.org/lookup/doi/10.1161/CIR.0000000000000558.
2. Vaidya V, Gangan N, Sheehan J, Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review. Expert Rev Pharmacoecon Outcomes Res [Internet] 2015;15:487–497. Available from: http://www.tandfonline.com/doi/full/10.1586/14737167.2015.1024661.
3. Stratton IM., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ Internet]. 2000;321:405–412. Available from: http://www.bmj.com/cgi/doi/10.1136/bmj.321.7258.405.
4. Gerstein G, Miller M, Byington R, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
5. Kheirbek RE, Alemi F, Zargoush M, et al. Comparative effectiveness of hypoglycemic medications among veterans. J Manag Care Pharm. 2013 Nov-Dec;19(9):740-744.
6. Flores E, Santos-Gallego CG, Diaz-Mejía N, et al. Do the SGLT-2 inhibitors offer more than hypoglycemic activity? Cardiovasc Drugs Ther. 2018;213–222.
7. Upadhyay J, Polyzos SA, Perakakis N, et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism Internet]. 2018;78:13–42.
8. American Diabetes Association AD. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care Internet]. 2018;41:S55–S64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29222377.
9. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–16.
10. Komajda M, Jjv M, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31:824–831.
11. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26:2983–2989.
12. Nissen S, Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;357:100.
13. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191–1201.
14. Erpeldinger S, Rehman MB, Berkhout C, et al. Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC Endocr Disord Internet]. 2016;16:1–15.
15. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110:955–961.
16. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–965.
17. Timmers L, Henriques JPS, DP V DK, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol Internet. 2009;53:501–510.
18. Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491–1499.
19. Sattar N, Petrie MC, Zinman B, et al. Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol. 2017;69:2646–2656.
20. Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013;15:204–212.
21. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med [Internet]. 2016;375:1834–1844. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1607141.
22. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes hhs public access. N Engl J Med. 2016;375:311–322.
23. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet]. 2017;NEJMoa1612917. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1612917.
24. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med [Internet]. 2015;373:2247–2257. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1509225.
25. Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6:105–113.
26. Scirica BM, Bhatt DL, E B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med [Internet]. 2013;369:1317–1326. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1307684.
27. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med [Internet]. 2013;369:1327–1335. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1305889.
28. Green JB, Ma B, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet]. 2015;373:232–242. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1501352.
29. Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr [Internet]. 2013;5:6. Available from: http://dmsjournal.biomedcentral.com/articles/10.1186/1758-5996-5-6.
30. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
31. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure systematic review of observational studies involving 34 000 patients. Circ Heart Fail. 2013;6:395–402.
32. Mogensen UM, Andersson C, Fosbøl EL, et al. Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study. Diabetologia. 2015;58:50–58.
33. Roumie CL, Min JY, D’Agostino McGowan L, et al. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J Am Heart Assoc [Internet]. 2017;6:e005379. Available from: http://jaha.ahajournals.org/lookup/doi/10.1161/JAHA.116.005379.
34. Ns G, Holman R, Haffner S, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463–1476.
35. Lee YC, Chang CH, Dong YH, et al. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study. Int J Cardiol Internet]. 2017;228:1007–1014.
36. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol Internet. 2017;13:11–26.
37. Freitas HS, Anhê GF, Melo KFS, et al. Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1α expression and activity. Endocrinology. 2008;149:717–724.
38. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427–3434.
39. Solini A, Rossi C, Mazzanti CM, et al. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:1289–1294.
40. Defronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36:3169–3176.
41. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13:669–672.
42. Polidori D, Sha S, Ghosh A, et al. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98:867–871.
43. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes. 2013;62:3324–3328.
44. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol Internet. 2012;8:495–502. Available from.
45. Madaan T, Akhtar M, Najmi AK. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharm Sci [Internet]. 2016;93:244–252.
46. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract [Internet]. 2014;104:297–322.
47. Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjectss. Drug Metab Dispos. 2013;41:445–456.
48. Sims H, Smith KH, Bramlage P, et al. Sotagliflozin: a dual sodium-glucose co-transporter-1 and −2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus. [Internet]. Diabet Med. 2018. Available from: http://doi.wiley.com/10.1111/dme.13645%0A, http://www.ncbi.nlm.nih.gov/pubmed/29637608.
49. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med [Internet]. 2017;NEJMoa1708337. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1708337.
50. Kadokura T, Zhang W, Krauwinkel W, et al. Clinical pharmacokinetics and pharmacodynamics of the novel sglt2 inhibitor ipragliflozin. Clin Pharmacokinet. 2014;53:975–988.
51. Kasahara-Ito N, Fukase H, Ogama Y, et al. Pharmacokinetics and pharmacodynamics of tofogliflozin (a selective sglt2 inhibitor) in healthy male subjects. Drug Res (Stuttg). 2017;67:349–357.
52. Novikov A, Vallon V. Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update. Curr Opin Nephrol Hypertens. 2016;25:50–58.
53. Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016;37:3192–3200b.
54. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154–1160.
55. Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium- glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730–1735.
56. Packers M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation. 2017;136:1548–1559.
57. Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+exchanger, lowering of cytosolic Na+and vasodilation. Diabetologia. 2018;61:722–726.
58. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab. 2015;100:1927–1932.
59. Al Jobori H, Daniele G, Adams J, et al. Empagliflozin treatment is associated with improved beta cell function in T2DM. J Clin Endocrinol Metab [Internet]. 2018;103:1402–1407. Available from: http://academic.oup.com/jcem/advance-article/doi/10.1210/jc.2017-01838/4801231.
60. Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032–2038.
61. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med [Internet]. 2015;373:2117–2128. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1504720.
62. Vijayakumar S, Vaduganathan M, Butler J. Glucose-lowering therapies and heart failure in type 2 diabetes mellitus. Circulation [Internet]. 2018;137:1060–1073. Available from: http://circ.ahajournals.org/lookup/doi/10.1161/CIRCULATIONAHA.117.032099.
63. Ferrannini E, Seman L, Seewaldt-Becker E, et al. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:721–728.
64. Hu H, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin type 2 diabetes. Diabetes Care. 2013;36:1–9.
65. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17:936–948.
66. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
67. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. Diabetes Care. 2013;;36(8):2154-2161.
68. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia. 2013;56:2582–2592.
69. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet Internet. 2013;382:941–950. Available from.
70. Neal B, Perkovic V, De Zeeuw D, et al. Efficacy and safety of canaglif lozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403–411.
71. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther. 2015;6:289–302.
72. Schernthaner G, Gary M. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who with metformin plus sulfonylurea. Diabetes Care. 2013;36:2508–2515.
73. List JF, Tang W, Woo V, et al. Sodium-glucose cotransport inhibition. Emerg Treat Technol. 2009;32:650–657.
74. Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: A phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013;15:432–440.
75. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes Care. 2010;33:2217–2224.
76. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446–456.
77. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–2233.
78. Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an sglt2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–1478.
79. Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–750.
80. Wilding JP, Woo V, Soler NG, et al. Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):405-415.
81. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721–728.
82. Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20:520–529.
83. Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther Internet]. 2018;9:253–268. Available from.;:.
84. Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab [Internet]. 2016;18:783–794. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27059700.
85. Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J [Internet]. 2018;39:363–370. Available from: https://academic.oup.com/eurheartj/article/39/5/363/4096345.
86. Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119–129.
87. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Programme Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377:644–657.
88. Patorno E, Goldfine AB, Schneeweiss S, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ [Internet]. 2018;k119. Available from http://www.bmj.com/lookup/doi/10.1136/bmj.k119.
89. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet]. 2018;NEJMoa1812389. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1812389.\.
90. Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. Jama [Internet]. 2018;319:1580. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.3024.
91. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
92. Dekkers CCJ, Petrykiv S, Laverman G, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab [Internet]. 2018;1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29573529%0Ahttp://doi.wiley.com/10.1111/dom.13301.
93. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. Accord Study Group. N Engl J Med. 2011 Mar 3;364(9):818-828.
94. Fitchett D, Butler J, Van De Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J. 2018;39:363–370.
95. Baartscheer A, Schumacher CA, Rci W, et al. Empagliflozin decreases myocardial cytoplasmic Na+through inhibition of the cardiac Na+/H+exchanger in rats and rabbits. Diabetologia. 2017;60:568–573.
96. Théroux P, Chaitman B, Danchin N, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation. 2000;102:3032–3038.
97. Zhang L, Jaswal JS, Ussher JR, et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail. 2013;6:1039–1048.
98. Wende AR, Brahma MK, McGinnis GR, et al. Metabolic origins of heart failure. JACC Basic to Transl Sci. 2017;2:297–310.
99. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a thrifty substrate hypothesis. Diabetes Care. 2016;39:1108–1114.
100. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
101. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
102. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65:1190–1196.
103. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. AJP Heart Circ Physiol [Internet]. 2013;304:H1060–H1076. Available from: http://ajpheart.physiology.org/cgi/doi/10.1152/ajpheart.00646.2012.
104. Santos-Gallego CG, Antonio J, Ibanez R, et al. Heart failure and cardiomyopathies EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION. J Am Coll Cardiol [Internet]. 2018;71:A674.
105. Cherney DZI, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:1–8.
106. Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180–1193.
107. Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39:e212–e213.
108. Habibi J, Aroor AR, Sowers JR, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:1–15.
109. Matsutani D, Sakamoto M, Kayama Y, et al. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol Internet. 2018;17:1–12. Available from.
110. Januzzi JL, Butler J, Jarolim P, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70:704–712.
111. Kimura G. Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure. Circ J [Internet]. 2016;80:2277–2281. Available from: https://www.jstage.jst.go.jp/article/circj/80/11/80_CJ-16-0780/_article.
112. Santos-Gallego CG, Zafar M, Antonio RS, et al. The SGLT2 inhibitor empagliflozin does not exhibit pro thrombotic effects. J Am Coll Cardiol Conf 67th Annu Sci Sess Am Coll Cardiol I2 Summit Innov Interv. ACC [Internet]. 2018;71:A1852. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexb&AN=621786327.
113. Kim Y-G, Jeon JY, Han SJ, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. Diabetes Obes Metab [Internet]. 2018;;20(8):1852-1858.
114. Tanaka A, Node K. Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? Cardiovasc Diabetology. 2017;16:17–19.
115. Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol [Internet]. 2017;5:680–681.